Moffitt Cancer Center Logo
 

Damon Reed, MD

Where You Are:
Damon Reed, MD

Assistant Member

Office  (813) 745-4292

Education And Training
  • Fellow, St. Jude Children's Hospital, 2008 - Pediatric Hematology Oncology
  • Intern & Resident, Boston Children's Hospital, 2005 - Pediatrics
  • MD, Case Western University School of Medicine, 2002


Dr. Reed’s research interest focuses on the prediction of conventional chemotherapy efficacy in non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) using ex vivo assays and xenograft models. The research of Dr. Reed’s group is conducted in Dr. Altiok’s laboratory in close collaboration and is focused on biomarker discovery and validation in order to predict clinical benefit in NRSTS. The work has focused on creating a panel of representative NRSTS xenografts from fresh, untreated human sarcomas and serially transplanting them through generations in immunodeficient mice.  Furthermore, fresh human tissue is tested ex vivo in the presence of clinically relevant chemotherapeutic agents and molecular pathways of DNA damage, cell cycle arrest and apoptosis; analysis includes, but is not limited to, PARP cleavage, gammaH2AX, and Rb.  Currently, through support from the Sarcoma Foundation of America, the xenografts are being treated in vivo with agents or combinations with correlative ex vivo results.

  • Kim M, Reed D, Rejniak KA. The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: A hybrid model study. J Theor Biol. 2014 Mar;352C:31-50. Pubmedid: 24607745.
  • Conley AP, Koplin S, Caracciollo JT, Reed DR, Webber NP, Attia S. Dramatic Response to Pazopanib in a Patient With Metastatic Malignant Granular Cell Tumor. J Clin Oncol. 2014 Feb. Pubmedid: 24550417.
  • Coccia PF, Pappo AS, Altman J, Bhatia S, Borinstein SC, Flynn J, Frazier AL, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack B, Shead DA, Sundar H. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Ne. 2014 Jan;12(1):21-32. Pubmedid: 24453290.
  • Foroutan P, Kreahling JM, Morse DL, Grove O, Lloyd MC, Reed D, Raghavan M, Altiok S, Martinez GV, Gillies RJ. Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy. PLoS One. 2013 Dec;8(12):e82875. Pubmedid: 24358232.
  • Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR. Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma. 2013 Nov;2013:365723. Pubmedid: 24282374. Pmcid: PMC3824404.
  • Kessler LM, Craig BM, Plosker SM, Reed DR, Quinn GP. Infertility evaluation and treatment among women in the United States. Fertil Steril. 2013 Oct;100(4):1025-1032.e2. Pubmedid: 23849845.
  • Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ, Altiok S. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One. 2013 Sep;8(3):e57523. Pubmedid: 23520471. Pmcid: PMC3592874.
  • Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ. Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis. 2013 Aug;4:e566. Pubmedid: 23538447. Pmcid: PMC3613821.
  • Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Netw. 2013 Jun;11(6):679-686. Pubmedid: 23744867.
  • Vohra NA, Turaga KK, Gonzalez RJ, Conley A, Reed D, Bui MM, Cheong D, Letson DG, Zager JS. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia. 2013 Jun;29(1):1-7. Pubmedid: 23205633.
  • Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER. Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol. 2013 Jun;3:141. Pubmedid: 23761859. Pmcid: PMC3674398.
  • Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol. 2013 May;5:147-162. Pubmedid: 23700373. Pmcid: PMC3660127.
  • Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371-382. Pubmedid: 23477833. Pmcid: PMC3766955.
  • Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012 Nov;19(12):3888-3895. Pubmedid: 22864798.
  • Koohbanani B, Han G, Reed D, Zhao Q, Yi D, Henderson-Jackson E, Bui MM. Ethnicity and age disparities in Ewing sarcoma outcome. Fetal Pediatr Pathol. 2012 Oct;32(4):246-252. Pubmedid: 23043418.
  • Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH, Beaupin LK, Link MP, Oeffinger KC, Orr KM, Pappo AS, Reed D, Spraker HL, Thomas DA, von Mehren M, Wechsler DS, Whelan KF, Zebrack BJ, Sundar H, Shead DA. Adolescent and young adult oncology. J Natl Compr Canc Netw. 2012 Sep;10(9):1112-1150. Pubmedid: 22956810.
  • Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells. Mol Cancer Ther. 2012 Jan;11(1):174-182. Pubmedid: 22084170.
  • Reed D, Altiok S. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine. Cancer Control. 2011 Jul;18(3):188-195. Pubmedid: 21666581.
  • Bui MM, Han G, Acs G, Reed D, Gonzalez RJ, Pasha TL, Zhang PJ. Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor. Sarcoma. 2011;2011:971050. Pubmedid: 21647307. Pmcid: PMC3103998.
  • Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem. 2010 Apr;285(14):10786-10796. Pubmedid: 20080970. Pmcid: PMC2856285.
  • Finelli DA, Reed DR. Flip angle dependence of experimentally determined T1sat and apparent magnetization transfer rate constants. J Magn Reson Imaging. 1998 May;8(3):548-553. Pubmedid: 9626867.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer